Procept BioRobotics said today that it won an Interventional Procedure Guidance recommendation from the UK’s National Institute for Health and Clinical Excellence for is Aquablation therapy as an alternative technique for treating benign prostatic hyperplasia.
The AquaBeam system uses a robotically controlled waterjet to ablate prostate tissue without needing heat, the Redwood Shores, Calif.-based company said
Procept BioRobotics also said that it won approval for a new technology add-on payment from the US Centers for Medicare and Medicaid Services for the Aquablation system.
“The NICE guidance is the first step in gaining full endorsement for widespread use of Aquablation in the UK. In addition, the recent CMS NTAP designation recognizes Aquablation therapy as a substantial clinical improvement compared to other surgical techniques for BPH and aligns with our vision of making Aquablation therapy the new standard of care and treatment of choice for BPH,” co-founder, CEO & prez Nikolai Aljuri said in a prepared statement.
“Studies comparing Aquablation therapy to TURP demonstrate that this new approach delivers outcomes like TURP but with a far lower risk of sexual dysfunction. The AquaBeam Robotic system offers a solution for patients regardless of prostate size and shape. The procedure is predictable and has provided reproducible outcomes, as it allows me to plan the surgery via ultrasound and then perform a controlled resection of the prostate via the autonomous AquaBeam robot,” consultatn urological surgeon Neil Barber of the UK’s Frimley Park Hospital said in a press release.
In May, ProCept BioRobotics released early results from a study of its AquaBeam waterjet ablation therapy system, touting that it already met its primary safety and efficacy endpoints.